SCHEMBL1641072

SCHEMBL1641072

CCCCNC(=O)c1c(O)c(C(=O)NCC(=O)O)c(=O)n(Cc2ccc(C)cc2C)c1O

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 6/20 0.51
KCNH2 Q12809 1/20 0.44
EGLN1 Q9GZT9 7/20 0.41
EGLN2 Q96KS0 3/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MAPT P10636 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
ALOX12 P18054 1/20 0.38
HTT P42858 1/20 0.38
ALDH1A1 P00352 1/20 0.38
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1640823 0.84 EGLN3 (0.52) EGLN3KCNH2EGLN1EGLN2
SCHEMBL1642263 0.84 EGLN3 (0.48) EGLN3EGLN1EGLN2
SCHEMBL1641965 0.83 EGLN3 (0.58) EGLN3KCNH2EGLN1EGLN2SMN1; SMN2
SCHEMBL1641706 0.80 EGLN3 (0.55) EGLN3KCNH2EGLN1EGLN2SMN1; SMN2
SCHEMBL1642619 0.80 EGLN3 (0.48) EGLN3EGLN1SMN1; SMN2KDM4EMAPT
SCHEMBL12727347 0.80 EGLN3 (0.59) EGLN3EGLN1EGLN2
SCHEMBL1642355 0.77 EGLN3 (0.40) EGLN3EGLN1EGLN2SMN1; SMN2KDM4E
SCHEMBL1642107 0.77 EGLN3 (0.53) EGLN3KCNH2EGLN1EGLN2SMN1; SMN2
SCHEMBL1641990 0.77 EGLN3 (0.62) EGLN3KCNH2EGLN1EGLN2MEN1
SCHEMBL1642767 0.76 EGLN1 (0.45) EGLN3KCNH2EGLN1SMN1; SMN2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS GLAXOSMITHKLINE LLC 2011-04-28 US disclosed
WO-2009158315-A1 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-12-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098324-A1 PROLYL HYDROXYLASE INHIBITORS HIF1AN, EGLN2, EGLN3 EGLN3 3/4885KCNH2 3889/4885EGLN1 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.